Key Highlights
- Revenue was USD 83.54 million against an estimate of USD 7.10 million.
- EPS was USD 0.80 against an estimate of a USD 0.24 loss.
- Net income was USD 58.15 million, against a USD 15.85 million loss.
- Cash and marketable securities were USD 156.2 million at September 30.
Foghorn Therapeutics (NASDAQ:FHTX) reported third quarter 2026 collaboration Revenue of USD 83.54 million, against an estimate of USD 7.10 million and USD 8.15 million in the third quarter of 2025. Diluted Net Income per share was USD 0.80, compared with an estimate of a USD 0.24 loss and a USD 0.25 loss a year earlier.
Net income was USD 58.15 million, against a net loss of USD 15.85 million in the prior-year quarter. Income from operations was USD 56.64 million, compared with a loss from operations of USD 18.50 million.
Operating Expenses
Total operating expenses were USD 26.90 million, compared with USD 26.65 million a year earlier. Research and Development expenses were USD 18.84 million, against USD 20.00 million, and general and administrative expenses were USD 5.80 million, against USD 6.65 million.
Other income, net was USD 1.5 million, compared with USD 2.7 million in the third quarter of 2025. The company reported these figures in its quarterly filing for the period ended September 30, 2026.
Nine-Month Results
For the nine months ended September 30, 2026, collaboration revenue was USD 102.88 million, against USD 21.66 million in the same period of 2025. Net income was USD 31.08 million, compared with a net loss of USD 52.62 million, and income from operations was USD 26.26 million, against a loss of USD 62.51 million.
Nine-month total operating expenses were USD 76.62 million, against USD 84.17 million. Research and development expenses for the period were USD 55.62 million, compared with USD 63.42 million, and general and administrative expenses were USD 18.73 million, against USD 20.75 million.
Liquidity and Financing
As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 156.2 million, including cash and cash equivalents of USD 80.30 million and marketable securities of USD 75.92 million. The filing states the company believes this is sufficient to fund its operating expenses and Capital Expenditure requirements for at least 12 months.
On January 9, 2026, the company entered into securities purchase agreements with life sciences investors for the sale of 2,030,314 shares of common stock and pre-funded warrants to purchase 5,421,250 shares. The filing also describes an at-the-market sales agreement originally entered into in April 2022 for shares with an aggregate offering price of up to USD 200.0 million, amended in March 2025. It cautions that there is no assurance research and development can be completed, that intellectual property protection can be maintained, that products can obtain required regulatory approval or that approved products can be commercially viable.
Foghorn Therapeutics Q3 2026 Earnings: Key Takeaways
Foghorn Therapeutics reported third quarter 2026 collaboration revenue of USD 83.54 million and diluted net income per share of USD 0.80. Net income was USD 58.15 million, and cash, cash equivalents and marketable securities were USD 156.2 million.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...